

Major shareholder transaction

Notification pursuant to Section 28a of the Danish Securities Trading Act

Copenhagen and Oslo, 6th September 2012

In accordance with Section 28a of the Danish Securities Trading Act, this is to notify, on behalf of Alexander Shuster, Chairman of the Board of Directors of Affitech A/S, of the following transactions:

Name	Trans Nova Investments Limited
Reason for reporting	Related party to Alexander Shuster, Chairman of the Board of Affitech A/S
Issuer and ISIN	Affitech A/S/DK0015966592
Type of transaction	Purchase of shares
Relevant market	NASDAQ OMX COPENHAGEN A/S
Date of transaction	5 th September, 2012
Number of traded securities and market value	97,573 shares. Market value DKK 19,466
Date of transaction	6 th September, 2012
Number of traded securities and market value	62,517 shares. Market value DKK 12,503

Contact

Randi Krosgaard, Director IR & Communications

Tel # +45 2320 1001, e-mail: ir@affitech.com

About Affitech

Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.